TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding TScan Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 92 | 81 | −11 |
| Shares | 40.1M | 35.7M | −4.41M (−11.0%) |
| Value | $55.4M | $51.8M | −$3.57M (−6.4%) |
New holders (21)
Institutions that held TScan Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 213,396 | $309.4K | 0.00% |
| Militia Capital Partners, LP | 94,300 | $136.7K | 0.06% |
| Y-Intercept (Hong Kong) Ltd | 76,660 | $111.2K | 0.00% |
| Qube Research & Technologies Ltd | 68,286 | $99.0K | 0.00% |
| HRT Financial LP | 55,369 | $80.0K | 0.00% |
| Marshall Wace, LLP | 53,678 | $77.8K | 0.00% |
| Jain Global LLC | 37,888 | $54.9K | 0.00% |
| Point72 Asia (Singapore) Pte. Ltd. | 29,070 | $42.2K | 0.01% |
| Algert Global LLC | 28,030 | $40.6K | 0.00% |
| Quadrature Capital Ltd | 22,500 | $32.9K | 0.00% |
| Squarepoint Ops LLC | 22,497 | $32.6K | 0.00% |
| AQR Capital Management LLC | 22,438 | $32.5K | 0.00% |
| Neuberger Berman Group LLC | 21,167 | $30.7K | 0.00% |
| JustInvest LLC | 19,892 | $28.8K | 0.00% |
| Catalyst Funds Management Pty Ltd | 18,000 | $26.1K | 0.01% |
| Dynamic Technology Lab Private Ltd | 13,878 | $20.0K | 0.00% |
| R Squared Ltd | 11,181 | $16.2K | 0.01% |
| DRW Securities, LLC | 10,132 | $14.7K | 0.00% |
| Rialto Wealth Management, LLC | 381 | $553 | 0.00% |
| Strategic Wealth Partners, Ltd. | 311 | $451 | 0.00% |
| Essential Partners LLC | 11 | $16 | 0.00% |
Sold out (32)
Institutions that held TScan Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.